BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 250 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q3 2021. The put-call ratio across all filers is 0.73 and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $272,000 | -24.7% | 1,802 | -30.7% | 0.00% | 0.0% |
Q3 2021 | $361,000 | +41.0% | 2,601 | -1.6% | 0.00% | +100.0% |
Q2 2021 | $256,000 | +75.3% | 2,642 | +23.6% | 0.00% | 0.0% |
Q1 2021 | $146,000 | -97.9% | 2,137 | -97.3% | 0.00% | -97.6% |
Q4 2020 | $6,909,000 | +29.9% | 80,607 | -1.5% | 0.04% | +24.2% |
Q3 2020 | $5,318,000 | -30.3% | 81,807 | -21.6% | 0.03% | -32.7% |
Q2 2020 | $7,626,000 | +120.3% | 104,308 | +2.5% | 0.05% | +104.2% |
Q1 2020 | $3,462,000 | -79.5% | 101,740 | -67.2% | 0.02% | -68.8% |
Q4 2019 | $16,900,000 | +55.5% | 310,439 | +19.2% | 0.08% | +54.0% |
Q3 2019 | $10,869,000 | +5.9% | 260,531 | +11.1% | 0.05% | +8.7% |
Q2 2019 | $10,268,000 | +917.6% | 234,486 | +772.3% | 0.05% | +1050.0% |
Q3 2018 | $1,009,000 | +52.4% | 26,880 | +9.5% | 0.00% | +100.0% |
Q4 2017 | $662,000 | -27.9% | 24,548 | 0.0% | 0.00% | -50.0% |
Q3 2017 | $918,000 | +125.0% | 24,548 | +50.6% | 0.00% | +100.0% |
Q2 2017 | $408,000 | – | 16,300 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 1,111,111 | $154,344,000 | 72.03% |
Knoll Capital Management, LLC | 856,844 | $119,024,000 | 59.36% |
ORACLE INVESTMENT MANAGEMENT INC | 2,124,055 | $295,053,000 | 36.73% |
ARS Investment Partners, LLC | 466,668 | $64,825,000 | 6.49% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 365,373 | $50,754,000 | 6.18% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $24,490,000 | 5.91% |
SILVERARC CAPITAL MANAGEMENT, LLC | 61,897 | $8,598,000 | 4.86% |
DAFNA Capital Management LLC | 88,100 | $12,238,000 | 3.25% |
Avidity Partners Management LP | 934,200 | $129,770,000 | 2.88% |
Eventide Asset Management | 1,325,000 | $184,056,000 | 2.43% |